New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”),…
CAMBRIDGE, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of…
MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other…
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company…
New additions enable clients to better connect pre-launch strategy through in-market execution—aligning intelligence and teams to drive effective launches and…
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that…
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and…
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt…
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of…